USD 7.04
(1.15%)
Year | Net Income | Net Income Growth |
---|---|---|
2023 | -892.86 Million USD | 57.58% |
2022 | -2.1 Billion USD | -15.02% |
2021 | -1.83 Billion USD | -1345.43% |
2020 | -126.6 Million USD | -6.1% |
2019 | -119.32 Million USD | 0.0% |
2001 | - USD | 0.0% |
Year | Net Income | Net Income Growth |
---|---|---|
2024 Q1 | -165.91 Million USD | 21.63% |
2024 Q2 | -217.18 Million USD | -30.9% |
2023 Q3 | -302.89 Million USD | -74.76% |
2023 Q1 | -204.96 Million USD | -16.1% |
2023 FY | -892.86 Million USD | 57.58% |
2023 Q2 | -173.31 Million USD | 15.44% |
2023 Q4 | -211.69 Million USD | 30.11% |
2022 Q3 | -670.13 Million USD | -0.2% |
2022 FY | -2.1 Billion USD | -15.02% |
2022 Q2 | -668.82 Million USD | -13.26% |
2022 Q1 | -590.5 Million USD | 63.11% |
2022 Q4 | -176.54 Million USD | 73.66% |
2021 FY | -1.83 Billion USD | -1345.43% |
2021 Q4 | -1.6 Billion USD | -1471.1% |
2021 Q3 | -101.88 Million USD | -88.87% |
2021 Q2 | -53.94 Million USD | 26.68% |
2021 Q1 | -73.56 Million USD | -56.78% |
2020 Q1 | -24.97 Million USD | 0.0% |
2020 FY | -126.6 Million USD | -6.1% |
2020 Q3 | -26.05 Million USD | 9.08% |
2020 Q4 | -46.92 Million USD | -80.1% |
2020 Q2 | -28.65 Million USD | -14.76% |
2019 FY | -119.32 Million USD | 0.0% |
2001 Q1 | -592.59 Million USD | 0.0% |
2001 Q3 | -669.05 Million USD | 0.23% |
2001 FY | - USD | 0.0% |
2001 Q2 | -670.57 Million USD | -13.16% |
Name | Net Income | Net Income Difference |
---|---|---|
ADC Therapeutics SA | -240.05 Million USD | -271.947% |
Alto Neuroscience, Inc. | -36.3 Million USD | -2359.355% |
Annovis Bio, Inc. | -56.2 Million USD | -1488.613% |
Biohaven Pharmaceutical Holding Company Ltd. | -408.16 Million USD | -118.75% |
Nuvation Bio Inc. | -75.8 Million USD | -1077.896% |
Nuvation Bio Inc. | -75.8 Million USD | -1077.896% |
Arcus Biosciences, Inc. | -307 Million USD | -190.837% |
Zymeworks Inc. | -118.67 Million USD | -652.371% |